Nestmedic, an innovative telemedicine company listed on NewConnect and the creator of Pregnabit mobile CTG, has signed an investment agreement with Agnieszka Kierner. A current member of the Supervisory Board is going to support the Company in its expansion to foreign markets. Agnieszka Kierner will take up 330,000 shares in the Company at the price of 1.50 PLN per share.
With the new investor and the capital injection of nearly half a million zloty, Nestmedic will be able to commercialise its flagship product – a mobile CTG device, known as Pregnabit, which is used to monitor fetal and maternal well-being at any time and anywhere, without having to visit a hospital or a clinic.
Agnieszka Kierner has been a corporate manager for 20 years. For many years, she worked as a HR director in one of the Polish start-ups which, following an impressive growth and success, was sold to tech giant, Atos. Her work was repeatedly acknowledged by various influential circles in the world of business. She has lived in the United States for many years now, currently in Boston – a centre of development of the medical, biomedical, pharmaceutical, and telemedical industries. She has long standing experience in investing in technological and telemedical businesses. A graduate of Executive MBA studies, a lecturer in management, strategic management and international human resource management at several international universities.
– Acquiring a new shareholder is a breakthrough for Nestmedic. We hope that new financial resources combined with experience and personal commitment of our new investor will make it possible for us to sign further commercial agreements on foreign markets. Starting from 2019, Pregnabit devices have also been available to patients in Finland and Bulgaria, comments Jacek Gnich, Nestmedic CEO.
